RenalSense

RenalSense

Realtime Renal Diagnostics

Founded 2010 Israel

Israel 11 employees Series A Total: $17.00M Biotechnology, Health Care

RenalSense is a biotechnology startup hailing from Israel, founded in 2009. The company's slogan, "Realtime Renal Diagnostics," perfectly encapsulates its mission to revolutionize renal diagnostics. RenalSense's flagship product, Clarity RMS, is a groundbreaking medical device that offers continuous monitoring of urine flow for real-time assessment of renal function and early detection and prevention of ICU-acquired Acute Kidney Injury (AKI). In the current medical landscape, over 30% of critical care patients develop AKI, resulting in significant additional hospital costs and high mortality rates reaching up to 83% for patients requiring dialysis. Renal function assessment in ICUs typically relies on manual and intermittent urine volume measurements, leading to subjective evaluations. This outdated approach results in delayed responses and can contribute to worsening patient outcomes. Clarity RMS represents a paradigm shift in this respect. It consists of an electronic sensor that seamlessly connects to a Foley catheter, enabling continuous and reliable measurement of urine flow. This data is automatically collected and transmitted, reducing human error and providing crucial real-time information, displayed graphically on a bedside monitor. In this context, the recent $14.00M Series A investment from BlueRed Partners at 22 November 2021 underscores the growing confidence in RenalSense's innovative approach. This injection of capital not only validates the potential of RenalSense but also highlights the crucial importance of advancements in medical technology, particularly in the context of critical care. With the backing of BlueRed Partners, RenalSense is poised to further develop and commercialize Clarity RMS, potentially reshaping renal diagnostics and positively impacting patient care in ICUs worldwide.

Funding Stage	Amount	Investors	Lead Investors	Date
Series A	$14.00M	1	BlueRed Partners	22 Nov 2021
Grant	ILS3.00M	1	Israel Innovation Authority	30 May 2019

Funding Stage

Amount

Investors

Lead Investors

Date

Series A

$14.00M

BlueRed Partners

22 Nov 2021

Grant

ILS3.00M

Israel Innovation Authority

30 May 2019

FAQ About RenalSense

Realtime Renal Diagnostics

RenalSense was founded in 2010.

RenalSense is headquartered in Israel.

RenalSense operates in Biotechnology and Health Care. Its work centres on renal diagnostics, critical care management, ICU-acquired Acute Kidney Injury and continuous monitoring.

RenalSense has approximately 11 employees.

RenalSense has completed 2 funding rounds, raising a total of $17.00M. The latest funding stage is Series A.

Top alternatives and competitors to RenalSense include Kantum Pharma, OptiScan Biomedical Corporation, GlucoSet, CritiSense, BioIntelliSense, Inc. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

RenalSense and Kantum Pharma are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About RenalSense

Funding Rounds & Investors (2)

RenalSense Alternatives & Competitors

FAQ About RenalSense